Pandemics are a clear-and-present danger to life as we know it. They have been with us for thousands of years, they are existential, and we still do not have a solution. Even in the present day, we remain structurally unprepared to combat infectious disease:
There is no market for diseases without incidence. The standard pharma industry model doesn’t work for most infectious diseases — especially sporadic ones.
Without a market to provide returns, there is no investment. Pandemic threat mitigation is almost exclusively a governmental undertaking.
Unleash the innovation already present in our universities, government labs, and small businesses.
NIAID is the world’s premiere funding source for infectious diseases, providing almost $6B/y to the best and brightest infectious disease researchers in the country. They are constantly inventing and discovering. They are not, however, equipped to turn an invention into a therapy.
An entrepreneurial, agile, executive, and purpose-built public-private partnership with a sharp focus on identifying and developing novel diagnostics, vaccines, prophylactics, and therapeutics would protect the country against pandemic-scale threats.
As an operating, drug-developing entity, this public-private partnership complements and supports BARDA and HHS.
Celdara Medical was purpose-built to transform academic innovations into high-impact medicines. In concert with our affiliates Virtici (Seattle) and MBV (Indianapolis), we already work with hundreds of academic institutions representing over $10B/year in NIH research funding.
Celdara is the fastest-growing company in the state of New Hampshire (in all sectors, based on 3-year AAGR) for each of the last three years, and has been in the top 10 for each of the last six years, winning accolades from the NIH, SBA, and various Federal, state, and local agencies, as well as national and international publications. We have established academic innovation networks worldwide, and “boots on the ground” in Boston, New York, Indianapolis (MBV), and Seattle (Virtici).
Furthermore, we have – with the support of the NIH – established multi-state partnerships to improve medical entrepreneurship in Vermont, New Hampshire, Maine, Rhode Island and Delaware, as well as seven additional Western states (Alaska, Hawaii, Idaho, Montana, Nevada, New Mexico, and Wyoming, which Virtici leads). We work with the country’s major contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), as well as most major biotech and pharma companies. Universities, pharmaceutical companies, CROs, and CDMOs to date have been unanimously supportive of the Pandemic Security Initiative.
A narrated introduction to the Pandemic Security Initiative
The Pandemic Security Initiative is an integral part of the solution. Scientific funding, research, and innovation processes already work well. In parallel, we must continue the repurposing of drugs developed for other indications, as well as the development of rapid-response platforms. There is, however, a development gap between the invention of new tests, vaccines, and therapies, and our ability to stockpile them. The Pandemic Security Initiative proactively identifies the most promising medical countermeasures, and develops them to approved products to remove this development gap.